These findings suggest that the ACE2/Ang1-7/Mas axis is essential for liraglutide-mediated amelioration of NAFLD, and that the PI3K/AKT pathway is the signaling mechanism through which liraglutide regulates the RAS. The gene discussed is ACE2; the disease is metabolic dysfunction-associated steatotic liver disease.